Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.

Watts JM, Wang XV, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Zickl L, Paietta E, Rowe JM, Tallman MS.

Leuk Res. 2014 Aug;38(8):901-6. doi: 10.1016/j.leukres.2014.05.018. Epub 2014 Jun 2.

PMID:
24986381
2.

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).

Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS.

Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22.

PMID:
22729365
3.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ Jr, Shapiro GR, Cassileth PA.

Leuk Lymphoma. 2012 Jun;53(6):1137-42. doi: 10.3109/10428194.2011.643406. Epub 2012 Jan 11.

PMID:
22111940
4.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2011 Apr;52(4):587-96. doi: 10.3109/10428194.2010.543714. Epub 2011 Jan 28.

PMID:
21275630
5.

Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).

Wiernik PH, Dutcher JP, Yao X, Venkatraj U, Falkson CI, Rowe JM, Cassileth PA.

J Immunother. 2010 Nov-Dec;33(9):1006-9. doi: 10.1097/CJI.0b013e3181f5dfc5.

PMID:
20948435
6.
7.

Effects of poverty and race on outcomes in acute myeloid leukemia.

Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC.

Am J Clin Oncol. 2011 Jun;34(3):297-304. doi: 10.1097/COC.0b013e3181dea934.

PMID:
20562587
8.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.

Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, Hahn T.

Biol Blood Marrow Transplant. 2008 Feb;14(2):137-80. doi: 10.1016/j.bbmt.2007.11.002. Review.

PMID:
18215777
9.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.

J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5.

PMID:
16754935
10.

Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Morgensztern D, Rosado MF, Raez LE, Santos ES, Cassileth PA.

Leuk Lymphoma. 2005 Feb;46(2):297-8. No abstract available.

PMID:
15621818
11.

Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).

Cassileth PA, Lee SJ, Litzow MR, Miller KB, Stadtmauer EA, Tallman MS, Lazarus HM, Bennett JM, Paietta E, Dewald GW, Rowe JM; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2005 Jan;46(1):55-61.

PMID:
15621781
12.

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.

Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER.

J Clin Oncol. 2004 Jul 15;22(14):2800-7.

PMID:
15254047
13.
14.

Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group.

Tallman MS, Kim HT, Paietta E, Bennett JM, Dewald G, Cassileth PA, Wiernik PH, Rowe JM; Eastern Cooperative Oncology Group.

J Clin Oncol. 2004 Apr 1;22(7):1276-86. Epub 2004 Feb 17.

PMID:
14970186
15.

Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.

Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER.

Cancer Gene Ther. 2003 Nov;10(11):850-8.

PMID:
14605671
16.
17.

Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.

Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group.

Leukemia. 2003 Aug;17(8):1544-50.

PMID:
12886241
18.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR.

Blood. 2000 Dec 15;96(13):4075-83.

PMID:
11110676
19.

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.

Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM.

Blood. 2000 Oct 1;96(7):2405-11.

PMID:
11001891
20.

Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).

Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA.

Leukemia. 2000 Aug;14(8):1349-53.

PMID:
10942228
21.

Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group.

Lee S, Tallman MS, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, Rowe JM.

Leukemia. 2000 Aug;14(8):1345-8.

PMID:
10942227
22.

Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.

Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA.

Am J Clin Oncol. 2000 Jun;23(3):273-7.

PMID:
10857892
23.
24.

A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA.

Blood. 1999 Nov 15;94(10):3307-14.

PMID:
10552939
25.

Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells.

Restrepo A, Albrecht F, Raez LE, Fernandez HF, Nassiri M, Byrne G Jr, Cassileth PA.

Crit Rev Oncog. 1999;10(3):239-45. Review.

PMID:
10468183
26.

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.

Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC.

Clin Cancer Res. 1999 Jul;5(7):1665-70.

PMID:
10430066
27.

Is central nervous system prophylaxis necessary in ocular adnexal lymphoma?

Restrepo A, Raez LE, Byrne GE Jr, Johnson T, Ossi P, Benedetto P, Hamilton K, Whitcomb CC, Cassileth PA.

Crit Rev Oncog. 1998;9(3-4):269-73.

PMID:
10201631
28.

Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL).

Raez LE, Patel P, Feun L, Restrepo A, Raub WA Jr, Cassileth PA.

Crit Rev Oncog. 1998;9(3-4):199-208.

PMID:
10201628
29.

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience.

Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH.

Leukemia. 1998 Dec;12(12):1881-5.

PMID:
9844918
30.

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH.

N Engl J Med. 1998 Dec 3;339(23):1649-56.

PMID:
9834301
31.

Interleukin-2 therapy for advanced chronic myeloid leukemia.

Goodman M, Spector N, Rodrigues G, Cassileth PA.

Leukemia. 1998 Nov;12(11):1682-4.

PMID:
9823941
32.

Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants.

Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth PA.

Bone Marrow Transplant. 1998 May;21(9):923-6.

PMID:
9613785
33.

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P.

J Clin Oncol. 1998 Mar;16(3):818-29.

PMID:
9508162
34.

Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group.

Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS, Bennett JM, Wiernik PH.

Br J Haematol. 1998 Feb;100(2):265-72.

PMID:
9488612
35.

A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.

Morrell LE, Lee YJ, Hurley J, Arias M, Mies C, Richman SP, Fernandez H, Donofrio KA, Raub WA Jr, Cassileth PA.

Cancer. 1998 Feb 1;82(3):503-11.

PMID:
9452268
36.

Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience.

Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E, Wiernik PH, Rowe JM.

Cancer. 1997 Dec 1;80(11 Suppl):2205-9.

PMID:
9395035
37.

Morphologic classification of acute myeloid leukemia: concordance among Eastern Cooperative Oncology Group investigators: a comment.

Bennett JM, Cassileth PA, Paietta E, Rowe JM, Wiernik PH.

Leukemia. 1996 Aug;10(8):1365. No abstract available.

PMID:
8709645
38.

Treatment of adult patients with acute lymphocytic leukemia in relapse.

Mazza JJ, Leong T, Rowe JM, Wiernik PH, Cassileth PA.

Leuk Lymphoma. 1996 Jan;20(3-4):317-9.

PMID:
8624473
39.

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH.

Blood. 1995 Jul 15;86(2):457-62.

PMID:
7605984
40.

The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.

Friedenberg WR, Miller HJ, Marx JJ Jr, Schloesser LL, Reding DJ, Mazza JJ, Hocking WG, Mercier RJ, Raich PC, Cassileth PA.

Am J Clin Oncol. 1995 Apr;18(2):105-10.

PMID:
7900701
41.

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, et al.

J Clin Oncol. 1995 Apr;13(4):974-82.

PMID:
7707126
42.

Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer.

Cassileth PA, Podack E, Sridhar K, Savaraj N, Hanlon J.

Hum Gene Ther. 1995 Mar;6(3):369-83. No abstract available.

PMID:
7779919
43.

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.

Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA.

Cancer. 1995 Feb 1;75(3):865-73.

PMID:
7530168
44.
45.

Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L.

Antimicrob Agents Chemother. 1993 Mar;37(3):474-82.

PMID:
8460916
46.

Autologous bone marrow transplant in acute myeloid leukemia in first remission.

Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein M, Oken MM.

J Clin Oncol. 1993 Feb;11(2):314-9.

PMID:
8426209
47.

Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.

Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH.

Leukemia. 1992 Nov;6 Suppl 4:75-7. No abstract available.

PMID:
1434840
48.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.

Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ.

Ann Hematol. 1992 Oct;65(4):162-8. Erratum in: Ann Hematol 1993 Mar;66(3):164. Kyungmann K [corrected to Kim K].

PMID:
1420504
49.

Phase II clinical trial of carboplatin in relapsed and refractory leukemia.

Vogler WR, Harrington DP, Winton EF, Lazarus HM, Bennett JM, Cassileth PA, Oken MM.

Leukemia. 1992 Oct;6(10):1072-5.

PMID:
1405761
50.

Recertification in hematology. Hematology Board of the American Board of Internal Medicine.

Nienhuis AW, Armitage JO, Cassileth PA, Foinstein DI, Furie BA, LaBuglio AF, Moore A.

Blood. 1992 Jul 15;80(2):564-5. No abstract available.

PMID:
1627812

Supplemental Content

Loading ...
Support Center